Competitor Monitoring Tracker — Zenvara Class (NSCLC Immunotherapy)
Maintained by Jordan Patel, CI Analyst. Updated weekly or on event-trigger. Distribution: VP Commercial, Medical Affairs Director, Launch Lead, MSL Lead.
Overview
The tracker monitors 6 directly-competitive assets in development across 5 sponsor companies, plus 4 watch-list assets in adjacent indications that could pivot into NSCLC. The most material change this week (May 14, 2026) is the CheckMate-X readout from BMS, which missed primary PFS in 2L NSCLC and substantially de-risks the competitive landscape for our ZENITH-2 program.
Active direct competitors (Phase 3)
BMS CheckMate-X (nivolumab + relatlimab combination) — 2L NSCLC. Phase 3 enrolled. STATUS UPDATE 2026-05-14: missed primary PFS endpoint (HR 0.91, p=0.18). BMS unlikely to pursue 2L label. Threat level: LOW (was HIGH).
Roche IMpower-YY (atezolizumab + bevacizumab) — 1L NSCLC PD-L1 high. Phase 3, readout expected Q3 2026. Threat level: MEDIUM. ASCO 2026 presentation: full data, Plenary Tuesday session.
AstraZeneca PACIFIC-ZZZ (durvalumab + new agent) — locally advanced NSCLC post-CRT. Phase 3, completed enrollment April 2025. Readout expected H1 2027. Threat level: MEDIUM (different patient population but could pivot to 1L metastatic if positive).
Merck KEYNOTE-WWW (pembrolizumab + new oral agent) — 1L NSCLC PD-L1 high. Phase 3, enrolling. Threat level: MEDIUM-HIGH (head-to-head positioning with Zenvara).
Novartis NIVA-001 (novel checkpoint inhibitor) — 1L NSCLC. Phase 3, completed enrollment Q1 2026. Readout expected mid-2027. Threat level: LOW-MEDIUM (limited supporting Phase 2 data).
AbbVie AGN-202 (anti-CTLA-4 + anti-PD-L1 combination) — 1L NSCLC. Phase 3 enrollment started 2026-04-18. Threat level: WATCH (early-stage; readout 2028+).
Adjacent watch list
Daiichi Sankyo DESTINY-Lung-XX (trastuzumab deruxtecan) — HER2-mutant NSCLC. Different biomarker population. Threat level: LOW.
Gilead Trodelvy + IO combinations — Phase 2 in NSCLC. Threat level: LOW (early-stage).
BMS-Exelixis Cabometyx + nivolumab — 1L NSCLC. Phase 2. Threat level: WATCH.
Sanofi/Regeneron Libtayo (cemiplimab) — 1L NSCLC PD-L1 high. Phase 3 mature data, Phase 4 ongoing. Threat level: LOW (already in market with limited 1L share).
Recent material events (rolling 90 days)
May 14, 2026: BMS CheckMate-X readout missed primary PFS. See ASCO 2026 Readout (1L9…) for detail.
April 28, 2026: BMS held investor briefing post-Q1 earnings; CFO acknowledged 'mixed Phase 3 readouts' in their oncology pipeline. Signal: BMS may pivot capital allocation away from late-stage NSCLC.
April 18, 2026: AbbVie AGN-202 Phase 3 enrollment began. AbbVie press release positioned the program as 'differentiated combination approach.' Investors and analysts received cautiously. Site activation in US, EU, China.
March 22, 2026: Roche presented IMpower-YY interim safety data at ELCC; no efficacy data. Safety profile consistent with prior atezolizumab + bevacizumab combinations.
March 8, 2026: Merck published KEYNOTE-WWW Phase 2b data in Lancet Oncology. ORR 52%, mPFS 11.2 months. Strong Phase 2b signal positions the Phase 3 favorably.
February 14, 2026: AstraZeneca PACIFIC-ZZZ enrollment milestone announcement. On track for H1 2027 readout.
January 30, 2026: Novartis NIVA-001 Phase 2 update at virtual investor event. Mixed signal; CIs wide.
Competitive landscape map (1L NSCLC PD-L1 high)
Currently in market: pembrolizumab (Merck, KEYNOTE-189, KEYNOTE-024 — original SoC, broad indication). Atezolizumab (Roche, IMpower130 in adenocarcinoma). Zenvara (zenvalimab — our product, ZENITH-1 positive). Cemiplimab (Sanofi/Regeneron, EMPOWER-Lung 1 — modest commercial uptake).
Approaching market: Roche IMpower-YY readout Q3 2026; Merck KEYNOTE-WWW readout 2027.
Watch: Novartis NIVA-001 readout mid-2027.
Implications
Near-term (next 6 months): CheckMate-X failure relieves competitive pressure in 2L NSCLC. Less defensive messaging required; focus on ZENITH-2 forward positioning.
Mid-term (6-18 months): IMpower-YY Q3 2026 readout is the next major competitive event. If positive, Roche becomes a real 1L PD-L1-high competitor; if negative, Zenvara consolidates 1L positioning further.
Long-term (18-36 months): KEYNOTE-WWW readout (2027) is the head-to-head with the current SoC. If positive, Merck differentiation strengthens against Zenvara; if negative, Zenvara has clearer 1L positioning. KEYNOTE-WWW Phase 2b data suggests a positive readout is more likely than not.
AbbVie AGN-202 is the only late-stage development asset entering the space in 2026; readout 2028+. Long enough horizon that strategic response should be on the indication-expansion side rather than defensive.
Monitoring sources
Conference abstract feeds (ASCO Meeting Library, ESMO ePoster system, ELCC), competitor earnings calls (quarterly), CT.gov enrollment data (monthly review), trade publications (FierceBiotech, EndPoints, BioCentury), KOL networks (MSL channel + sponsored advisory boards).
Automated alerts configured for: CT.gov status changes on tracked trials, sponsor IR materials on competitor programs, FDA approval announcements in indication.
Cross-references
ASCO 2026 Readout (1L9…), KOL Advisory Board Apr 2026 Synthesis (1M2…), 2026 Congress Calendar (1O8…).